{"id":"NCT02420821","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)","officialTitle":"A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-20","primaryCompletion":"2020-02-14","completion":"2021-12-13","firstPosted":"2015-04-20","resultsPosted":"2018-10-03","lastUpdate":"2023-01-30"},"enrollment":915,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["Tecentriq, MPDL3280A"]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Sunitinib","otherNames":["Sutent"]}],"arms":[{"label":"Atezolizumab + Bevacizumab","type":"EXPERIMENTAL"},{"label":"Sunitinib","type":"ACTIVE_COMPARATOR"}],"summary":"This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.","primaryOutcome":{"measure":"Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population","timeFrame":"Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months)","effectByArm":[{"arm":"Sunitinib","deltaMin":69.6,"sd":null},{"arm":"Atezolizumab + Bevacizumab","deltaMin":58.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":154,"countries":["United States","Australia","Bosnia and Herzegovina","Brazil","Canada","Czechia","Denmark","France","Germany","Italy","Japan","Mexico","Poland","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37146227","34940781","32127394","31079938"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":169,"n":446},"commonTop":["DIARRHOEA","HYPERTENSION","FATIGUE","NAUSEA","DECREASED APPETITE"]}}